北美car-T细胞疗法治疗市场规模，份额，行业分析，增长，趋势和预测2028年

市场分析与洞察：北美 CAR-T 细胞治疗市场

CAR-T 细胞疗法治疗市场预计将在 2021 年至 2028 年的预测期内实现市场增长。Data Bridge Market Research 分析，在 2021 年至 2028 年的预测期内，该市场以 29.9% 的复合年增长率增长，预计到 2028 年将达到 56.9288 亿美元。CAR-T 细胞疗法在癌症和传染病治疗中的使用增加成为 CAR-T 细胞疗法治疗市场增长的驱动力。

CAR-T 细胞疗法或嵌合抗原受体 T 细胞是经过基因改造的 T 细胞，用于产生人工 T 细胞受体，可用作治疗各种癌症的免疫疗法。嵌合抗原受体是在实验室中设计的受体蛋白，可为 T 细胞提供针对特定蛋白质的新型能力。

人们对免疫疗法的认识不断提高，使人们接触到多种 CAR-T 疗法及其有效性，从而成为 CAR-T 细胞疗法市场发展的驱动力。疗法的不良副作用限制了一些人群选择这种疗法，从而影响了产品价值，因此限制了 CAR-T 细胞疗法市场的增长。管道产品的存在表明市场参与者不断从事创新药物的生产，因此为 CAR-T 细胞疗法市场提供了机会。免疫疗法的审批时间较长，限制了产品制造商在市场上获得潜在利益，并影响了整体市场规模，因此对 CAR-T 细胞疗法市场的增长构成了挑战。

CAR-T 细胞疗法治疗市场报告提供了市场份额、新发展和产品线分析、国内和本地市场参与者的影响的详细信息，分析了新兴收入领域、市场法规变化、产品批准、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情况，请联系我们获取分析师简报，我们的团队将帮助您创建收入影响解决方案，以实现您的预期目标。

北美 CAR-T 细胞治疗市场范围和市场规模

CAR-T 细胞疗法治疗市场根据产品、结构、靶向抗原、品牌、治疗应用、最终用户和分销渠道进行细分。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。

根据产品，CAR-T 细胞疗法治疗市场细分为自体 CAR-T 细胞和同种异体 CAR-T 细胞。2021 年，自体 CAR-T 细胞细分市场预计将主导 CAR-T 细胞疗法治疗市场，因为获批用于 CAR-T 细胞疗法的药物本质上是自体的。
根据结构，CAR-T 细胞疗法治疗市场分为第一代 CAR-T 细胞、第二代 CAR-T 细胞、第三代 CAR-T 细胞和第四代 CAR-T 细胞。2021 年，第二代 CAR-T 细胞部分预计将主导 CAR-T 细胞疗法治疗市场，因为已获批准的疗法是基于第二代的结构。
根据靶向抗原，CAR-T 细胞疗法治疗市场细分为实体肿瘤抗原、血液系统恶性肿瘤抗原和其他抗原。2021 年，血液系统恶性肿瘤抗原细分市场预计将主导 CAR-T 细胞疗法治疗市场，因为获批用于 CAR-T 细胞疗法的药物主要用于血液系统恶性肿瘤，并且正在进行广泛的研究开发。
根据品牌，CAR-T 细胞疗法治疗市场细分为 yescarta、kymriah、tecartus 等。2021 年，yescarta 细分市场预计将主导 CAR-T 细胞疗法治疗市场，因为 yescarta 是首个获批的肿瘤治疗类 CAR-T 细胞疗法。
根据治疗应用，CAR-T 细胞疗法治疗市场细分为血液系统恶性肿瘤、胰腺癌、乳腺癌、肺癌、胃癌、多发性骨髓瘤、慢性淋巴细胞白血病、套细胞淋巴瘤、滤泡性淋巴瘤、弥漫性大 B 细胞淋巴瘤、急性淋巴细胞白血病等。2021 年，血液系统恶性肿瘤领域预计将主导 CAR-T 细胞疗法治疗市场，因为 yescarta 占市场的主要收入，而滤泡性淋巴瘤是 yescarta 的主要适应症。
根据最终用户，CAR-T 细胞疗法治疗市场分为医院、专科诊所和其他。2021 年，医院部门在 CAR-T 细胞疗法治疗市场中占据主导地位，因为 CAR-T 细胞疗法需要训练有素的专业人员和先进的技术实验室。

CAR-T 细胞疗法治疗市场国家层面分析

对 CAR-T 细胞疗法治疗市场进行分析，并根据上述国家、产品、结构、靶向抗原、品牌、治疗应用、最终用户和分销渠道提供市场规模信息。

北美 CAR-T 细胞治疗市场报告涵盖的国家包括美国、墨西哥和加拿大

美国在北美 CAR-T 细胞疗法治疗市场占据主导地位，预计在 2021 年至 2028 年的预测期内将以最高的增长率增长，原因是自体 CAR-T 细胞领域的医疗保健支出不断增加且医疗保健基础设施完善。

报告的国家部分还提供了影响单个市场因素和国内市场法规变化，这些变化影响了市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在提供国家数据的预测分析时，还考虑了北美品牌的存在和可用性以及由于来自本地和国内品牌的激烈或稀少的竞争而面临的挑战、销售渠道的影响。

免疫疗法认知度的提高推动了 CAR-T 细胞疗法市场的增长

CAR-T 细胞疗法治疗市场还为您提供有关 CAR-T 细胞疗法治疗行业每个国家增长情况的详细市场分析，包括 CAR-T 细胞疗法治疗销售、CAR-T 细胞疗法治疗技术进步的影响以及监管环境的变化及其对 CAR-T 细胞疗法治疗市场的支持。数据涵盖 2011 年至 2019 年的历史时期。

竞争格局和 CAR-T 细胞治疗市场份额分析

CAR-T 细胞疗法治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对 CAR-T 细胞疗法治疗市场的关注有关。

从事 CAR-T 细胞疗法治疗的主要公司包括 Atara Biotherapeutics, Inc.、Amgen Inc.、Bellicum Phamaceuticals, Inc.、bluebird bio, inc.、Adaptimmune Therapeutics plc.、Bristol-Myers Squibb Company、Xyphos (A Subsidiary of Astellas Pharma Inc.)、Johnson & Johnson Services, Inc.、BioAtla Inc.、Novartis AG、Kite Pharma (A Subsidiary of Gilead Sciences, Inc.)、Aurora Biopharma、Tmunity Therapeutics、Cartherics Pty ltd、Ziopharm Oncology, Inc.、Cellectis、Mustang Bio、Sorrento Therapeutics, Inc.、TC BIOPHARM、Celyad Oncology、Tessa Therapeutics Ltd 以及其他国内和全球参与者。DBMR 分析师了解竞争优势并为每个竞争对手分别提供竞争分析。

全球范围内，多家公司推出了许多产品并签署了多项协议，这也加速了CAR-T细胞疗法市场的发展。

例如，

2020 年 12 月，Atara Biotherapeutics, Inc. 与拜耳公司合作开发针对实体瘤的间皮素靶向 CAR-T 细胞疗法。根据协议，该公司高度专注于开发 ATA2271，以治疗恶性胸膜间皮瘤和非小细胞肺癌。此次合作加速了该公司对 ATA2271 的研发，并使其成为领先的同种异体 CAR-T 细胞疗法制造商。

市场参与者的合作、产品发布、业务扩展、奖励和认可、合资企业和其他策略正在增强公司在 CAR-T 细胞疗法治疗市场中的市场，这也为组织改善其在 CAR-T 细胞疗法治疗方面的产品提供了好处。

SKU-61533

Get online access to the report on the World's First Market Intelligence Cloud

Click on image to enlarge

Interactive Data Analysis Dashboard
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking

Request for Demo

表格列表

TABLE 1 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, PIPELINE ANALYSIS

TABLE 2 BELOW PROVIDED ARE THE ALTERNATIVE CHEMOTHERAPIES OF CAR-T CELL THERAPY:

TABLE 3 TOTAL HEALTH SPENDING BY THE U.S. (2015-2016)

TABLE 4 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET, BY MOLECULE, 2019-2028 (USD MILLION)

TABLE 5 NORTH AMERICA AUTOLOGOUS CAR-T CELLS IN CAR-T CELL THERAPY TREATMENTMARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 6 NORTH AMERICA ALLOGENEIC CAR-T CELLS IN CAR-T CELL THERAPY TREATMENTMARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET, BY STRUCTURE, 2019-2028 (USD MILLION)

CELYAD IS ENGAGED IN THE MANUFACTURING OF CYAD-211, A FIRST GENERATION CAR-T CELL THERAPY EXPRESSING BCMA TARGETING CHIMERIC ANTIGEN RECEPTOR WHICH INTERFERES WITH THE EXPRESSION OF THE CD3Ζ OF T CELL RECEPTOR COMPLEX.

TABLE 8 NORTH AMERICA FIRST GENERATION CAR-T CELLS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 9 NORTH AMERICA SECOND GENERATION CAR-T CELLS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 10 NORTH AMERICA THIRD GENERATION CAR-T CELLS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 11 NORTH AMERICA THIRD GENERATION CAR-T CELLS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 12 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 13 NORTH AMERICA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 14 NORTH AMERICA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY ANTIGENS ON HEMATOLOGIC MALIGNANCIES, 2019-2028 (USD MILLION)

TABLE 15 NORTH AMERICA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENTMARKET , BY REGION, 2017-2028 (USD MILLION)

TABLE 16 NORTH AMERICA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY ANTIGENS ON SOLID TUMORS, 2019-2028 (USD MILLION)

TABLE 17 NORTH AMERICA OTHERS IN CAR-T CELL THERAPY TREATMENTMARKET , BY REGION, 2017-2028 (USD MILLION)

TABLE 18 NORTH AMERICA YESCARTA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 19 NORTH AMERICA YESCARTA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 20 NORTH AMERICA KYMRIAH IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 21 NORTH AMERICA TECARTUS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 22 NORTH AMERICA OTHERS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 23 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)

TABLE 24 NORTH AMERICA FOLLICULAR LYMPHOMA IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC TYPE, 2017-2028 (USD MILLION)

TABLE 25 NORTH AMERICA DIFFUSE LARGE B-CELL LYMPHOMA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 26 NORTH AMERICA ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 27 NORTH AMERICA MANTLE CELL LYMPHOMA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 28 NORTH AMERICA MULTIPLE MYELOMA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 29 NORTH AMERICA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 30 NORTH AMERICA HEMATOLOGIC MALIGNANCIES ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 31 NORTH AMERICA LUNG CANCER IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 32 NORTH AMERICA CHRONIC LYMPHOCYTIC LEUKEMIA IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 33 NORTH AMERICA GASTRIC CANCER IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 34 NORTH AMERICA PANCREATIC CANCER IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 35 NORTH AMERICA BREAST CANCER IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 36 NORTH AMERICA OTHERS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 37 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 38 NORTH AMERICA HOSPITALS IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC TYPE, 2017-2028 (USD MILLION)

TABLE 39 NORTH AMERICA SPECIALTY CLINICS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 40 NORTH AMERICA OTHERS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 41 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 42 NORTH AMERICA HOSPITAL PHARMACY IN CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2017-2028 (USD MILLION)

TABLE 43 NORTH AMERICA OTHERS IN CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2017-2028 (USD MILLION)

TABLE 44 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 45 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 46 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)

TABLE 47 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 48 NORTH AMERICA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 49 NORTH AMERICA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 50 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)

TABLE 51 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 52 NORTH AMERICA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 53 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 54 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 55 U.S CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 56 U.S CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)

TABLE 57 U.S CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 58 U.S ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 59 U.S ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 60 U.S CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)

TABLE 61 U.S CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 62 U.S HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 63 U.S CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 64 U.S CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 65 CANADA CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 66 CANADA CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)

TABLE 67 CANADA CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 68 CANADA ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 69 CANADA ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 70 CANADA CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)

TABLE 71 CANADA CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 72 CANADA HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 73 CANADA CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 74 CANADA CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 75 MEXICO CAR-T CELL THERAPY TREATMENT MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 76 MEXICO CAR-T CELL THERAPY TREATMENT MARKET, BY STRUCTURE 2019-2028 (USD MILLION)

TABLE 77 MEXICO CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 78 MEXICO ANTIGENS ON HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 79 MEXICO ANTIGENS ON SOLID TUMORS IN CAR-T CELL THERAPY TREATMENT MARKET, BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

TABLE 80 MEXICO CAR-T CELL THERAPY TREATMENT MARKET, BY BRAND, 2019-2028 (USD MILLION)

TABLE 81 MEXICO CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 82 MEXICO HEMATOLOGIC MALIGNANCIES IN CAR-T CELL THERAPY TREATMENT MARKET, BY THERAPEUTIC APPLICATION, 2019-2028 (USD MILLION)

TABLE 83 MEXICO CAR-T CELL THERAPY TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 84 MEXICO CAR-T CELL THERAPY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

图片列表

FIGURE 1 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: MULTIVARIATE MODELLING

FIGURE 7 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 9 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: MARKET PRODUCT COVERAGE GRID

FIGURE 11 NORTH AMERICA IS EXPECTED TO DOMINATE THE NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 12 INCREASING INVESTMENT IN RESEARCH AND DEVELOPMENT IS EXPECTED TO DRIVE THE NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 AUTOLOGUS CAR-T CELLS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET

FIGURE 15 NEW CANCER CASES WORLDWIDE, (2018)

FIGURE 16 NORTH AMERICA CANCER INCIDENCE (2018)

FIGURE 17 CANCER DEATH BY TYPE (IN MILLION), WORLD, 2017

FIGURE 18 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, 2021

FIGURE 19 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, 2019-2028 (USD MILLION)

FIGURE 20 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, CAGR (2021-2028)

FIGURE 21 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 22 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, 2021

FIGURE 23 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, 2019-2028 (USD MILLION)

FIGURE 24 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, CAGR (2021-2028)

FIGURE 25 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET: BY STRUCTURE, LIFELINE CURVE

FIGURE 26 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET: BY TARGETED ANTIGENS, 2021

FIGURE 27 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET: BY TARGETED ANTIGENS, 2019-2028 (USD MILLION)

FIGURE 28 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET: BY TARGETED ANTIGENS, CAGR (2021-2028)

FIGURE 29 NORTH AMERICA CAR-T CELL THERAPY TREATMENTMARKET: BY TARGETED ANTIGENS, LIFELINE CURVE

FIGURE 30 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, 2020

FIGURE 31 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, 2020-2028 (USD MILLION)

FIGURE 32 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, CAGR (2020-2028)

FIGURE 33 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY BRAND, LIFELINE CURVE

FIGURE 34 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTIC APPLICATION, 2020

FIGURE 35 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTIC APPLICATION, 2020-2028 (USD MILLION)

FIGURE 36 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTIC APPLICATION, CAGR (2020-2028)

FIGURE 37 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY THERAPEUTIC APPLICATION, LIFELINE CURVE

FIGURE 38 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY END USER, 2020

FIGURE 39 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION)

FIGURE 40 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY END USER, CAGR (2020-2028)

FIGURE 41 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 42 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 43 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

FIGURE 44 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)

FIGURE 45 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 46 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: SNAPSHOT (2020)

FIGURE 47 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY COUNTRY (2020)

FIGURE 48 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY COUNTRY (2021 & 2028)

FIGURE 49 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY COUNTRY (2020 & 2028)

FIGURE 50 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: BY PRODUCT (2021-2028)

FIGURE 51 NORTH AMERICA CAR-T CELL THERAPY TREATMENT MARKET: COMPANY SHARE 2020 (%)

查看详细信息

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

At what growth rate will the market be projected to grow by forecast 2028?

North America CAR-T Cell Therapy Treatment Market to grow at a CAGR 29.9% by forecast 2028.

What will be the market value in the future?

North America CAR-T Cell Therapy Treatment Market value to reach USD 5,692.88 million by forecast 2028.

Who are the major players operating in the market?

The major companies which are dealing in the CAR-T cell therapy treatment are Atara Biotherapeutics, Inc., Amgen Inc., Bellicum Phamaceuticals, Inc., bluebird bio, inc., Adaptimmune Therapeutics plc., Bristol-Myers Squibb Company, Xyphos (A Subsidiary of Astellas Pharma Inc.), Johnson & Johnson Services, Inc., BioAtla Inc., Novartis AG, Kite Pharma (A Subsidiary of Gilead Sciences, Inc.), Aurora Biopharma, Tmunity Therapeutics, Cartherics Pty ltd, Ziopharm Oncology, Inc., Cellectis, Mustang Bio, Sorrento Therapeutics, Inc., TC BIOPHARM, Celyad Oncology, Tessa Therapeutics Ltd.

Which countries data are covered in the report?

The countries covered in the North America CAR-T cell therapy treatment market report are the U.S, Mexico, and Canada

北美 CAR-T 细胞疗法治疗市场 - 行业趋势和 2028 年预测

北美 CAR-T 细胞疗法治疗市场 - 行业趋势和 2028 年预测

市场分析与洞察：北美 CAR-T 细胞治疗市场

北美 CAR-T 细胞治疗市场范围和市场规模

CAR-T 细胞疗法治疗市场国家层面分析

竞争格局和 CAR-T 细胞治疗市场份额分析

Get online access to the report on the World's First Market Intelligence Cloud

目录

表格列表

图片列表

研究方法

可定制

Frequently Asked Questions

报告

市场洞察

支持

解决方案

北美 CAR-T 细胞疗法治疗市场 - 行业趋势和 2028 年预测

北美 CAR-T 细胞疗法治疗市场 - 行业趋势和 2028 年预测

市场分析与洞察：北美 CAR-T 细胞治疗市场

北美 CAR-T 细胞治疗市场范围和市场规模

CAR-T 细胞疗法治疗市场国家层面分析

竞争格局和 CAR-T 细胞治疗市场份额分析

Get online access to the report on the World's First Market Intelligence Cloud

目录

表格列表

图片列表

研究方法

可定制

Frequently Asked Questions

浏览相关页面